Medical Hypotheses
Volume 58, Issue 1 , Pages 47-60 , January 2002

The central role of magnesium deficiency in Tourette's syndrome: causal relationships between magnesium deficiency, altered biochemical pathways and symptoms relating to Tourette's syndrome and several reported comorbid conditions

Received 5 April 2001 ,Accepted 9 July 2001.

References 

  1. Coffey BJ, Miguel EC, Savage CR, Rauch SL. Tourette's disorder and related problems: a review and update. Harv Rev Psychiatry. 1994;2:121–132
  2. de Mattos JP, de Rosso AL. [Tics and Gilles de la Tourette syndrome]. Arq Neuropsyquiatr. 1995;53:141–146
  3. Jankovic J. Tourette syndrome: phenomenology, pathophysiology, genetics, epidemiology and treatment. Curr Neurol. 1992;13:8
  4. Scahill L, Ort S, Hardin M. Tourette's Syndrome. Part I: definition and diagnosis and Tourette's syndrome. Part II: Contemporary approaches to assessment and treatment. Arch Psychiat Nurs. 1993;7:203–216
  5. Suchowersky O. Gilles de la Tourette Syndrome. Can J Neurol Sci. 1994;21:48–52
  6. Dursun SM, Reveley MA. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psychol Med. 1997;27:483–487
  7. Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996;11:563–566
  8. Comings DE, Comings BG. Tourette syndrome: clinical and psychological aspects of 250 cases. Am J Hum Genet. 1985;37:718
  9. Kurlan R, Lichter D, Hewitt D. Sensory tics in Tourette's syndrome. Neurology. 1989;39:731–734
  10. Kim H, Moote W, Mazza J. Tourette's syndrome in patients referred for allergy evaluation. Ann Allergy Asthma Immunol. 1997;79:347–349
  11. Bullen JG, Hemsley DR. Sensory experience as a trigger in Gilles de la Tourette's syndrome. J Behav Ther Exp Psychiatry. 1983;14:197–201
  12. Scahill LD, Leckman JF, Marek KL. Sensory phenomena in Tourette's syndrome. Adv Neurol. 1995;65:273–280
  13. Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la Tourette's syndrome. J Clin Psychiatry. 1992;53:319–323
  14. Chokka PR, Baker GB, Bornstein RA, de Groot CM. The biochemistry of Tourette's syndrome. Metabolic Brain Disease. 1995;10:107–124
  15. Gronbech-Jensen M. [Gilles de la Tourette syndrome]. [Review]. Ugeskrift for Laeger. 1993;155:3759–3763
  16. Moldofsky H, Tullis C, Lamon R. Multiple tic syndrome (Gilles de la Tourette's syndrome). J Nerv Ment Dis. 1974;15:282–292
  17. Cohen DJ, Leckman JF, Pauls D. Neuropsychiatric disorders of childhood: Tourette's syndrome as a model. Acta Paediatr Suppl. 1997;22:106–111
  18. Castellanos, F. X. Giedd, J. N. Elia, J. et al., Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose, J Am Acad Child Adolesc Psychiatry, 36, 589, 596
  19. Peterson B S. Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. J Clin Psychiatry. 1996;57:24–34
  20. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med. 1994;148:859–861
  21. Price RA, Leckman JF, Pauls DL, Cohen DJ, Kidd KK. Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins. Neurology. 1986;36:232–237
  22. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. JAMA. 1982;247:1168–1169
  23. Pollack MA, Cohen NL, Friedhoff AJ. Gilles de la Tourette's syndrome. Familial occurrence and precipitation by methylphenidate therapy. Arch Neurol. 1977;34:630–632
  24. Dietl T, Kumpfel T, Hinze-Selch D, Trenkwalder C, Lechner C. [Exacerbation of tics by prednisolone]. [Article in German]. Nervenarzt. 1998;69:1111–1114
  25. Merette C, Brassard A, Potvin A. Significant linkage for Tourette syndrome in a large French Canadian family. Am J Hum Genet. 2000;67:1008–1013
  26. Merette C, Brassard A, Potvin A. Significant linkage for Tourette syndrome in a large French Canadian family. Am J Hum Genet. 2000;67:1008–1013
  27. Simonic I, Gericke GS, Ott J, Weber JL. Identification of genetic markers associated with Gilles de la Tourette syndrome in an Afrikaner population. Am J Hum Genet. 1998;63:839–846
  28. Simonic I, Gericke GS, Ott J, Weber JL. Identification of genetic markers associated with Gilles de la Tourette syndrome in an Afrikaner population. Am J Hum Genet. 1998;63:839–846
  29. Coffey BJ, Miguel EC, Savage CR, Rauch SL. Tourette's disorder and related problems: a review and update. Harv Rev Psychiatry. 1994;2:121–132
  30. Park S, Como PG, Cui L, Kurlan R. The early course of the Tourette's syndrome clinical spectrum. Neurology. 1993;43:1712–1715
  31. Sverd J. Tourette syndrome and autistic disorder: a significant relationship. Am J Med Genet. 1991;39:173–179
  32. McDougal CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord. 1990;20:537–543
  33. Feifel D. Attention-deficit hyperactivity in adults. Postgrad Med. 1996;100:207–211, 215–218
  34. Comings DE. Role of genetic factors in human sexual behavior based on studies of Tourette syndrome and ADHD probands and their relatives. Am J Med Genet. 1994;54:227–241
  35. Singer C. Tourette syndrome. Coprolalia and other coprophenomena. Neurol Clin. 1997;15:299–308
  36. Zohar AH, Pauls DL, Ratzoni G. Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Am J Psychiatry. 1997;154:274–276
  37. Eapen V, Moriarty J, Robertson MM. Stimulus induced behaviours in Tourette's syndrome. J Neurol Neurosurg Psychiatry. 1994;57:853–855
  38. Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la Tourette's syndrome. J Clin Psychiatry. 1992;53:319–323
  39. Comings DE, Comings BG. A controlled study of Tourette syndrome. I. Attention-deficit disorder, learning disorders, and school problems. Am J Hum Genet. 1987;41:701–741
  40. Summerfeldt LJ, Endler NS. Examining the evidence foranxiety-related cognitive biases in obsessive-compulsive disorder. J Anxiety Disord. 1998;12:579–598
  41. Chappell P, Riddle M, Anderson G. Enhanced stress responsitivity of Tourette syndrome patients undergoing lumbar puncture. Biological Psychiatry. 1994;36:35–43
  42. Wodrich DL, Benjamin E, Lachar D. Tourette's syndrome and psychopathology in a child psychiatry setting. J Am Acad Child Adolesc Psychiatry. 1997;36:1618–1624
  43. Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorders: a pilot study. J Clin Psychiatry. 1998;59:576–580
  44. Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette's disorder. J Clin Psychiatry. 1998;59:581–584
  45. Buitelaar J K. Self-injurious behaviour in retarded children: clinical phenomena and biological mechanisms. Acta Paedopsychiatr. 1993;56:105–111
  46. Scahill L, Van Wattum PJ. Asthma, allergies and TS. Tourette Syndrome Association Inc. Newsletter. 1996;24:3,13
  47. Ho CS, Shen EY, Shyur SD, Chiu NC. Association of allergy with Tourette's syndrome. J Formos Med Assoc. 1999;98:492–495
  48. Marshall P. Attention deficit disorder and allergy: a neurochemical model of the relation between the illnesses. Psychol Bull. 1989;106:434–446
  49. Boris M, Mandel FS. Foods and additives are common causes of the attention deficit hyperactive disorder in children. Ann Allergy. 1994;72:462–468
  50. Gerrard JW, Richardson JS, Donat J. Neuropharmacological evaluation of movement disorders that are adverse reactions to specific foods. Int J Neurosci. 1994;7:61–69
  51. Finegold I. Allergy and Tourette's syndrome. Annals of Allergy. 1985;55:119–121
  52. Barabas G, Matthews WS, Ferrari M. Tourette's syndrome and migraine. Arch Neurol. 1984;41:871–872
  53. Voderholzer U, Muller N, Haag D, Riemann D, Straube A. Periodic limb movements during sleep are a frequent finding in patients with Gilles de la Tourette's syndrome. J Neurol. 1997;244:521–526
  54. Pichietti DL, Underwood DJ, Farris , W A. Further studies on periodic limb movement disorder and restless legs syndrome in children with attention deficit hyperactivity disorder. Movement Disorders. 1999;14:1000–1007
  55. Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1995;34:307–311
  56. Swedo SE, Leonard HL, Mittleman BB. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry. 1997;154:110–112
  57. Comings, D. E. Genetic factors in substance abuse based on studies of Tourette Syndrome and ADHD probands and relatives. II. Alcohol abuse, Drug Alcohol Depend, 1994, 35, 17, 24
  58. Rayssiguier Y, Guezennec CY, Durlach J. New experimental and clinical data on the relationship between magnesium and sport. Magnes Res. 1990;3:93–102
  59. Durlach J, Bac P, Durlach V, Bara M, Guiet-Bara A. Neurotic, neuromuscular and autonomic nervous form of magnesium imbalance. Magnes Res. 1997;10:169–195
  60. Galland L. Magnesium, stress and neuropsychiatric disorders. Magnes Trace Elem. 1991;10:287–301
  61. Langley WF, Mann D. Central nervous system magnesium deficiency. Arch Intern Med. 1991;151:593–596
  62. Goto Y, Nakamura M, Abe S, Kato M, Fukui M. Physiological correlates of abnormal behaviors in magnesium-deficient rats. Epilepsy Research. 1993;15:81–89
  63. Holvey, D. N. The Merck Manual, Rahway, NJ, Merck Sharp & Dohme Research Laboratories, 1972, 1091
  64. Ploceniak C. [Bruxism and magnesium, my Clinical experiences since 1980]. [Article in French]. Rev Stomatol Chir Maxillofac. 1990;91:127
  65. Seelig M S. Interrelationship of magnesium and estrogen in cardiovascular and bone disorders, eclampsia, migraine and premenstrual syndrome. J Am Coll Nutr. 1993;12:442–458
  66. Thomas J, Tomb E, Thomas E, Faure G. Migraine treatment by oral magnesium intake and correction of the irritation of buccofacial and cervical muscles as a side effect of mandibular imbalance. Magnes Res. 1994;7:123–127
  67. Lehvila P. Bruxism and magnesium. Literature review and case reports. Proc Finn Dent Soc. 1974;70:217–224
  68. Ploceniak C. [Bruxism and magnesium, my clinical experiences since 1980]. [Article in French]. Rev Stomatol Chir Maxillofac. 1990;91:127
  69. Popoviciu L, Asgian B, Delast-Popoviciu D, Alexandrescu A, Petrutiu S, Bagathal I. Clinical, EEG, electromyographic and polysomnographic studies in restless legs syndrome caused by magnesium deficiency. Rom J Neurol Psychiatry. 1993;31:55–61
  70. Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep. 1998;21:501–505
  71. Fantidis P, Ruiz Cacho J, Marin M, Madero Jrabo R, Solera J, Herrero E. Intracellular (Polymorphonuclear) magnesium content in patients with bronchial asthma between attacks. J R Soc Med. 1995;88:441–445
  72. Galland L. Magnesium, stress and neuropsychiatric disorders. Magnes Trace Elem. 1991;10:287–301
  73. Goto Y, Nakamura M, Abe S, Kato M, Fukui M. Physiological correlates of abnormal behaviours in magnesium-deficient rats. Epilepsy Research. 1993;15:81–89
  74. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. Philadelphia: W. B. Saunders Company; 1994; p. 1953–1954
  75. Iakupova LP, Smirnov Alu, Kozlova IA, Gorbachevskaia NL, Kozhushko LF. [Various neurophysiological aspects of examination of children with Gilles de la Tourette's syndrome]. [Article in Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91:57–59
  76. Friedlander AH, Cummings JL. Dental treatment of patients with Gilles de la Tourette's syndrome. Oral Surg Oral Med Oral Pathol. 1992;73:299–303
  77. Muller N, Voderholzer U, Kurtz G, Straube A. Tourette's syndrome associated with restless legs syndrome and akathisia in a family. Acta Neurol Scand. 1994;89:429–432
  78. Lin CK, Hsu WY, Wang PJ, Shen YJ. [Gilles de la Tourette syndrome associated with epileptiform discharges; report of three cases]. [Chinese]. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih. 1989;30:61–65
  79. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5:24–27
  80. Gaudin-Harding F, Claverie-Benureau S, Armier J, Davy J, Lebel B. Aromatic amines (serotonin and histamine) and magnesium deficiency in the rat. Int J Vitam Nutr Res. 1980;50:185–192
  81. Galland L. Magnesium and immune function: an overview. [Review]. Magnesium. 1988;7:290–299
  82. Claverie-Benureau S, Lebel B, Gaudin-Harding F. Changes in histamine and white blood cells in the blood, spleen and thymus of magnesium deficient rat. Reprod Nutr Dev. 1981;21:591–600
  83. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. Philadelphia: W. B. Saunders Company; 1994; p. 1953–1954
  84. Zeana C D. Recent data on mitral valve prolapse and magnesium deficit. Magnes Res. 1988;1:203–211
  85. Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder (ADHD). Magnes Res. 1997;10:143–148
  86. Starobrat-Hermelin B. [The effect of deficiency of selected bioelements on hyperactivity in children with certain specified mental disorders]. [Article in Polish]. Ann Acad Med Stetin. 1998;44:297–314
  87. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit disorder (ADHD). Positive response to magnesium oral loading test. Magnes Res. 1997;10:149–156
  88. Meij IC, Saar K, van den Heuvel LP. Hereditary isolated renal magnesium loss maps to chromosome 11q23. Am J Hum Genet. 1999;64:180–188
  89. Weglicki WB, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Phillips TM. Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Molecular & Cellular Biochemistry. 1994;130:103–109
  90. Weglicki WB, Dickens BF, Wagner TL, Chmielinska JJ, Phillips TM. Immunoregulation by neuropeptides in magnesium deficiency: ex vivo effect of enhanced substance P production on circulating T lymphocytes from magnesium-deficient mice. Magnes Res. 1996;9:3–11
  91. Mak IT, Komarov AM, Wagner TL, Stafford RE, Dickens BF, Weglicki WB. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am J Physiol. 1996;271:C385–C390
  92. Shibata Y, Takeuchi F, Tsubouchi R. On kynureninase activity. Adv Exp Med Biol. 1991;294:523–526
  93. Rickards H, Dursun SM, Farrar G, Betts T, Corbett JA, Handley SL. Increased plasma kynurenine and its relationship to neopterin and tryptophan In Tourette's syndrome. Psychological Medicine. 1996;26:857–862
  94. Rudzite V, Sileniece G, Liepina D, Dalmane A, Zirne R. In:  Schwarcz R,  Young SN,  Brown RR editor. Kynurenine and Serotonin Pathways. New York: Plenum Press; 1991;p. 663–668
  95. Orlikov A, Ryzov I. Caffeine-induced anxiety and increase of kynurenine concentration in plasma of healthy subjects: a pilot study. Biol Psychiatry. 1991;29:391–396
  96. Shibata Y, Takeuchi F, Tsubouchi R. On kynureninase activity. Adv Exp Med Biol. 1991;294:523–526
  97. Gunther T, Ising H, Joachims Z. Biochemical mechanisms affecting susceptibility to noise-induced hearing loss. Am J Otol. 1989;10:36–41
  98. Chappell P, Riddle M, Anderson G. Enhanced stress responsitivity of Tourette syndrome patients undergoing lumbar puncture. Biological Psychiatry. 1994;36:35–43
  99. Leckman JF, Goodman WK, Anderson GM. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995;12:73–86
  100. Handley SL, Miskin RC. The interaction of some kynurenine pathway metabolites with 5-hydroxytryptophan and5-hydroxytryptamine. Psychopharmacology. 1977;51:305–309
  101. Pinelli A, Govoni S, Ossi C, Battaini F, Caimi BR, Trivulzio S. Kynurenine may directly interact with GABA receptors in rat brain. Pharmacology. 1985;30:255–258
  102. Lapin IP, Prakhie IB, Kiseleva IP. Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: differences between rats and mice. Neural Transm. 1982;54:229–238
  103. McGeer PL, McGeer EG. Amino acid neurotransmitters. In:  Seigel GJ editors. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. New York: Raven Press; 1989;p. 311–332
  104. Goetz CG. Clonidine and clonazepam in Tourette syndrome. In:  Chase TN,  Friedhoff AJ,  Cohen DJ editor. Advances in Neurology, Vol. 58, Tourette Syndrome: Genetics, Neurobiology and Treatment. New York: Raven Press; 1992;p. 245–251
  105. Hewlett W A. The use of benzodizepines in obsessive compulsive disorder and Tourette's syndrome. Pyschiat Ann. 1993;23:417–424
  106. Dewey SL, Chaurasia CS, Chen CE. GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse. 1997;25:393–398
  107. Thomas RJ, Reagan DR. Association of Tourette-like syndrome with ofloxacin. Annals of Pharmacotherapy. 1996;30:138–141
  108. Mendelson S D. Intraventricular administration of I-kynurenine and kynuramine facilitates lordosis in the female rat. Eur J Pharmacol. 1987;142:447–451
  109. Planells E, Lerma A, Sanchez-Morito N, Aranda P, Llopis J. Effect of magnesium deficiency on vitamin B2 and B6 status in the rat. J Am Coll Nutr. 1997;16:352–356
  110. Tryfiates GP. Vitamin B6 Metabolism and Role in Growth. Westport: Food & Nutrition Press Inc; 1980; p. 151
  111. Tryfiates GP. Vitamin B6 Metabolism and Role in Growth. Westport: Food & Nutrition Press Inc; 1980; p. 246–248
  112. Weglicki WB, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Phillips TM. Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Mol Cell Biochem. 1994;130:103–109
  113. Bender DA, Njagi ENM, Danielian PS. Comparison of tryptophan metabolism in vivo and in isolated hepatocytes from vitamin B6 deficient mice. Adv Exp Med Biol. 1991;294:359–368
  114. Gal EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. [Review]. Neurochemical Research. 1980;5:223–239
  115. Comings D E. Blood serotonin and tryptophan in Tourette syndrome. Am J Med Genet. 1990;36:418–430
  116. Brett PM, Curtis D, Robertson MM, Gurling HM. Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior. Am J Psychiatry. 1995;152:437–440
  117. Politi B, Lavaggi MV, De Luca G, Gorini A. The Role of Transaminations in Pharmacological Effects of Indole-3-Pyruvic Acid. In:  Schwarcz R,  Young SN,  Brown RR editor. Kynurenine and Serotonin Pathways. New York: Plenum Press; 1991;p. 603–606
  118. Holvey DN. The Merck Manual. Rahway: Merck Sharp & Dohme Research Laboratories; 1972; p. 1091
  119. Allgood VE, Cidlowski JA. Vitamin B6 modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. J Biol Chem. 1992;267:3819–3824
  120. Tully DB, Allgood VE, Cidlowski JA. Modulation of steroid receptor-mediated gene expression by vitamin B6. [Review]. FASEB. 1994;8:343–349
  121. Bender DA, Njagi ENM, Danielian PS. Comparison of tryptophan metabolism in vivo and in isolated hepatocytes from vitamin B6 deficient mice. Adv Exp Med Biol. 1991;294:359–368
  122. Tryfiates GP. Vitamin B6 Metabolism and Role in Growth. Westport: Food & Nutrition Press Inc; 1980; p. 301
  123. Wurtman RJ, Wurtman JJ. Nutrition and the Brain. New York: Raven Press; 1979; p. 206–211
  124. Viswanathan M, Paulose CS, Lal KJ, Sharma SK, Dakshinamurti K. Alterations in brainstem alpha 2 adrenoreceptor activity in pryidoxine-deficient rat model of hypertension. Neurosci Lett. 1990;111:201–205
  125. Turnlund JR, Betshchart AA, Liebman M, Kretsch MJ, Sauberlich HE. Vitamin B-6 depletion followed by repletion with animal- or plant-source diets and calcium and magnesium metabolism in young women. Am J Clin Nutr. 1992;56:905–910
  126. Nakamura M, Abe S, Goto Y, Chishaki A, Akazawa K, Kato M. In vivo assessment of prevention of white-noise-induced siezure in magnesium-deficient rats by N-methyl-D-aspartate receptor blockers [published erratum appears in Epilepsy Res 1994; 18 (1): 89. Epilepsy Res. 1994;17:249–256
  127. Foster AC, Fagg GE. Neurobiology. Taking apart NMDA Receptors. Nature. 1987;329:325–326
  128. Adamec RE, Burton P, Shallow T, Budgell J. Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle – effective hemisphere depends on the behavior. Physiol Behav. 1999;65:739–751
  129. Freese A, Swartz KJ, During MJ, Martin JB. Kynurenine metabolites of tryptophan: implications for neurologic diseases. [Review]. Neurology. 1990;40:691–695
  130. Saito K. [Biochemical studies on AIDS dementia complex-possible contribution of quinolinic acid during brain damage]. [Review] [Japanese]. Rinsho Byori. 1995;43:891–901
  131. McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutametergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res. 2000;877:23–30
  132. Weiner M, Van Eys J. Nicotinic Acid. New York: Marcel Dekker, Inc; 1983; p. 27
  133. Takaiwa P, Habara-Ohkubo A, Yoshida R. Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogeneic mouse: interferon-gamma is the inducer. Adv Exp Med Biol. 1991;294:437–446
  134. Schwarcz R, Seciale C, French ED. Hippocampal kynurenines as etiological factors in seizure disorders. [Review]. Polish J Pharmacol Pharm. 1987;39:485–494
  135. Stepien A. [The role of nitrogen oxide in migraine attack]. Neurol Neurochir Pol. 1999;33:435–444
  136. Arts M, Bemelmans F, Cools A. Activation of N-methyl-D-aspartate receptors in the feline retrorubral nucleus elicits orofacial dyskinesia. Eur J Pharmacol. 1998;349:23–31
  137. Wolf SS, Jones DW, Knable MB. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996;273:1225–1227
  138. Nankai M, Klarica M, Fage D, Carter C. The pharmacology of native N-methyl-D-aspartate receptor subtypes: different receptors control the release of different striatal and spinal transmitters. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:35–64
  139. Hussain N, Flumerfelt BA, Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience. 2001;102:391–399
  140. Pollack AE, Bird JL, Lambert EB, Florin ZP, Castellar VL. Role of NMDA glutamate receptors in regulating D2 dopamine-dependent fos induction in the rat striatopallidal pathway. Brain Res. 1999;818:543–547
  141. Alsobrook JP2nd, Pauls DL. Molecular approaches to child psychopathology. Hum Biol. 1998;70:413–432
  142. Weglicki WB, Dickens BF, Wagner TL, Chmielinska JJ, Phillips TM. Immunoregulation by neuropeptides in magnesium deficiency: ex vivo effect of enhanced substance P production on circulating T lymphocytes from magnesium-deficient mice. Magnes Res. 1996;9:3–11
  143. Pernow, B. Research on Tachykinins: Clinical Trends, Henry, J. L.Couture, R.Cuello, A. C.Pelletier, G.Quirion, R.Regoli, D. Substance P and Neurokinins, New York, Springer Verlag, 1987, 372, 378
  144. Liminga U. Selective neurokinin NK1 and NK2 receptor agonists infused in the substantia nigra of the rat increase vacuous chewing. Eur J Pharmacol. 1993;235:177–181
  145. Beckstead R M. Striatal substance P cell clusters coincide with the high density terminal zones of the discontinuous nigrostratal dopaminergic projection system in the cat: a study by combined immunohistochemistry and autoradiographic axon-tracing. Neuroscience. 1987;20:557–576
  146. Sivam S P. Dopamine, serotonin and tachykinin in self-injurious behavior. [Review]. Life Sciences. 1996;58:2367–2375
  147. Kramer MS, Cutler N, Feighner J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 1998;281:1640–1645
  148. Culman J, Klee S, Ohlendorf C, Unger T. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. J Pharmacol Exp Ther. 1997;280:238–246
  149. Swann JM, Newman SW. Testosterone regulates substance P within neurons of the medial nucleus of the amygdala, the bed nucleus of the stria terminalis and the medial preoptic area of the male golden hamster. Brain Res. 1992;590:18–28
  150. Fehder WP, Sach J, Uvaydova M, Douglas SD. Substance P as an immune modulator of anxiety. Neuroimmunomodulation. 1997;4:42–48
  151. File S E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav. 1997;58:747–752
  152. Hasenohrl RU, Jentjens O, De Souza Silva MA, Tomaz C, Huston JP. Anxiolytic-like action of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region. Eur J Pharmacol. 1998;354:123–133
  153. Shaikh MB, Steinberg A, Siegel A. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Res. 1993;625:283–294
  154. Aebischer I, Stampfli MR, Miescher S, Horn M, Zurcher AW, Stadler BM. Neuropeptides accentuate interleukin-4 induced human immunoglobuline E Synthesis in vitro. Experimental Dermatology. 1996;5:38–44
  155. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch- associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 1998;86:1140–1145
  156. Kokumai S, Imamura T, Masuyama K, Kambara T, Ishikawa T. Effect of capsaicin as a neuropeptide-releasing substance on sneezing reflex in a type I allergic animal model. Int Arch Allergy Immunol. 1992;98:256–261
  157. Widdicombe J G. Sensory neurophysiology of the cough reflex. J Allergy Clin Immunol. 1996;98:S84–S89
  158. Fang SY, Shen CL, Ohyama M. Distribution and quantity of neuroendocrine markers in allergic rhinitis. Acta Otolaryngol (Stockh). 1998;118:398–403
  159. Suzuki H, Miura S, Liu YY, Tsuchiya M, Ishii H. Substance P induces degranulation of mast cells and leukocyte adhesion to venular endothelium. Peptides. 1995;16:1447–1452
  160. Mori K, Asakura S, Morikawa N. [Seasonal fluctuations of substance P and vasoactive intestinal peptide concentrations in nasal secretions of patients with nasal allergy to Japanese cedar pollen]. [Japanese]. Arerugi. 1992;41:1651–1657
  161. Torrens Y, Dietl M, Beaujouan JC, Glowinski J. Inhibitory effects of Substance P and carbachol on the saturable sodium-dependent uptake process myo-inositol in rat parotid gland. J Pharmacol Exp Ther. 1991;258:638–646
  162. Yorek MA, Dunlap JA, Stefani MR, Davidson EP, Zhu X, Eichberg J. Decreased myo-inositol uptake is associated with reduced bradykinin-stimulated phosphatidylinositol synthesis and diacylglycerol content in cultured neuroblastoma cells exposed to L-fucose. J Neurochem. 1994;62:147–158
  163. Altura BM, Gebrewold A, Altura BT, Brautbar N. Magnesium depletion impairs myocardial carbohydrate and lipid metabolism and cardiac bioenergietics and raises myocardial calcium content in-vivo: relationship to etiology of cardiac diseases. Biochem Mol Biol Int. 1994;40:1183–1190
  164. De Camilli P, Emr SD, McPherson PS, Novick P. Phosphoinositides as regulators in membrane traffic. Science. 1996;271:1533–1539
  165. Hoyter D, Clarke DE, Fozard JR. VII International Union of Pharmacology classification of receptors for5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157–203
  166. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:53–60
  167. Weglicki WB, Dickens BF, Wagner TL, Chmielinska JJ, Phillips TM. Immunoregulation by neuropeptides in magnesium deficiency: ex vivo effect of enhanced substance P production on circulating T lymphocytes from magnesium-deficient mice. Magnes Res. 1996;9:3–11
  168. Rickards H, Dursun SM, Farrar G, Betts T, Corbett JA, Handley SL. Increased plasma kynurenine and its relationship to neopterin and tryptophan in Tourette's syndrome. Psychological Medicine. 1996;26:857–862
  169. Singh V K. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol. 1996;66:143–145
  170. Gupta S, Aggarwal S, Rashanravan B, Lee T. Th1- and Th2- like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol. 1998;85:106–109
  171. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol. 1997;159:2994–2999
  172. Ravidran AV, Griffiths J, Merali Z, Anisman H. Circulation lymphocyte subsets in obsessive compulsive disorder, major depression and normal controls. J Affect Disord. 1999;52:1–10
  173. Bac P, Herrenknecht C, Binet P, Durlach J. Audiogenic seizures in magnesium-deficient mice: effects of magnesium pyrrolidone-2-carboxylate, magnesium acetyltaurinate, magnesium chloride and vitamin B-6. Magnesium Research. 1993;6:11–19
  174. Wolf G, Keilhoff G, Fischer S, Hass P. Subcutaneously applied magnesium protects reliably against quinolinate-induced N-methyl-D-aspartate (NMDA)-mediated neurodegeneration and convulsions in rats: are there therapeutical implications. Neurosci Lett. 1990;117:207–211
  175. Bac P, Pages N, Dhalluin S, Tapiero H. Protective effect of Crassostrea gigas extract on audiogenic seizures in magnesium deficient mice. Biomed Pharmacother. 1998;52:162–165
  176. Huang QF, Gebrewold A, Altura BT, Altura BM. Mg2+ protects against PCP-induced cerebrovasospasms and vascular damage in rat brain. Magnes Trace Elem. 1990;9:44–46
  177. Caspi J, Coles JG, Benson LN, Wilson GJ. Brain damage and myocardial dysfunction: protective effects of magnesium in the newborn pig. Ann Thorac Surg. 1998;65:1730–1736
  178. Micheli F, Lekhumiec E, Magone C, Fernandez Pardal M, Pikielny R, Casas Parera I. Treatment of Tourette's syndrome with calcium antagonists. Clin Neuropharmacol. 1990;13:77–83
  179. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5:24–27
  180. Starobrat-Hermelin B. [The effect of deficiency of selected bioelements on hyperactivity in children with certain specified mental disorders]. [Article in Polish]. Ann Acad Med Stetin. 1998;44:297–314
  181. Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. [Review]. Journal of Child Neurology. 1988;3:68–72
  182. Bender DA, Njagi ENM, Danielian PS. Comparison of tryptophan metabolism in vivo and in isolated hepatocytes from vitamin B6 deficient mice. Advances in Experimental Medicine Biology. 1991;294:359–368
  183. Salter M, Beams RM, Critchley MAE, Hodson HF. Effects of Tryptophan 2, 3-Dioxygenase Inhibitors in the Rat. In:  Schwarcz R,  Young SN,  Brown RR editor. Kynurenine and Serotonin Pathways. New York: Plenum Press; 1991;p. 281–288
  184. Ohta Y, Sasaki E, Nishida K, Ishiguro I. Tryptophan transport into the liver of Vitamin B6-deficient rats. In:  Filippini GA,  Costa VL,  Bertazzo A editor. Recent Advances in Tryptophan Research. New York: Plenum Press; 1996;p. 589
  185. Lapin I P. Nicotinamide, inosine and hypoxanthine, putative endogenous ligands of the benzodiazepine receptor, opposite to diazepam are much more effective against kynurenine-induced seizures than against pentylenetetrazol- induced seizures. Pharmacol Biochem Behav. 1981;14:589–593
  186. Sunderland GT, Belch JJ, Sturrock RD, Forbes CD, McKay AJ. A double blind randomised placebo controlled trial of hexopal in primary Raynoud's disease. Clin Rheumatol. 1988;7:46–49
  187. Tanabe K, Noda K, Mikawa T, Murayama M, Sugai J. Magnesium content of erythrocytes in patients with vasospasic angina. Cardiovasc Drugs Ther. 1991;5:677–680
  188. Gasser P. Clinical syndromes with vasoconstrictor response. Wien Klin Wochenschr. 1991;103:217–221
  189. Mainetti C, Fathi M, Saurat JH. L-trytophan-induced eosinophilia- myalgia syndrome. II. Partial correction of abnormal tryptophan metabolism by pyridoxine. Dermatologica. 1991;183:62–65
  190. Hao R, Pfeiffer RF, Ebadi M. Purification and characterization of mlothionein and its activation of pyridoxal phosphokinase in trout (Salmo gairdneri) brain. Comp Biochem Physiol [B]. 1993;104:293–298
  191. Frye PE, Arnold EL. Persistent Amphetamine-Induce Compulsive Rituals: Response to Pyridoxine (B6). Biological Psychiatry. 1981;16:583–587
  192. Yaryura-Tobias J A. Gilles de la Tourette syndrome. Interactions with other neuropsychiatric disorders. Acta Psychiatrica Scandinavica. 1979;59:9–16
  193. Calviello G, Ricci P, Lauro L, Palozza P, Cittadini A. Mg deficiency induces mineral content changes and oxidative stress in rats. Biochemistry & Molecular Biology International. 1994;32:903–911
  194. Hsu JM, Smith JC, Yunice AA, Kepford G. Impairment of ascorbic acid synthesis in liver extracts of magnesium-deficient rats. J Nutr. 1983;113:2041–2047
  195. Mak IT, Komarov AM, Wagner TL, Stafford RE, Dickens BF, Weglicki WB. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am J Physiol. 1996;271:C385–C390
  196. Freedman AM, Atrakchi AH, Cassidy MM, Weglicki WB. Magnesium deficiency-induced cardiomyopathy: protection by vitamin E. Biochem Biophys Res Commun. 1990;170:1102–1106
  197. Weglicki WB, Phillips TM, Mak IT. Cytokines, neuropeptides, and reperfusion injury during magnesium deficiency. Ann N Y Acad Sci. 1994;723:246–257
  198. Adler LA, Peselow E, Rotrosen J. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry. 1993;150:1405–1407
  199. Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacology. 1993;8:151–153
  200. Hagerman AE, Butler LG. The specificity of proanthocyanidin-protein interactions. J Biol Chem. 1981;256:4494–4497
  201. Wyczolkowska J, Maslinski C. Inhibition by nicotinamide of antigen-induced histamine release from mouse peritonial mast cells. Int Arch Allergy Appl Immunol. 1976;50:729–736
  202. Garcia M, Gonzalez R. [Effect of pyridoxine on histamine liberation and degranulation of rat mast cells]. Allergol Immunopathol (Madr). 1979;7:427–432
  203. Kakegawa H, Matsumoto H, Endo K, Satoh T, Nonaka G, Nishioka I. Inhibitory effects of tannins on hyaluronidase activation and on the degranulation from rat mesentery mast cells. Chem Pharm Bull. 1985;33:5079–5082
  204. Sato M, Maulik G, Ray PS, Bagchi D, Das DK. Cardioprotective effects of grape seed proanthocyanidin against ischemic reperfusion injury. J Mol Cell Cardiol. 1999;31:1289–1297
  205. Altura BM, Gebrewold A, Altura BT, Brautbar N. Magnesium depletion impairs myocardial carbohydrate and lipid metabolism and cardiac bioenergietics and raises myocardial calcium content in-vivo: relationship to etiology of cardiac diseases. Biochem Mol Biol Int. 1994;40:1183–1190
  206. Rosenberg GS, Davis KL. The use of cholinergic precursors in neuropsychiatric diseases. Am J Clin Nutr. 1982;36:709–720
  207. Rahman S, Neuman RS. Myo-inositol reduces serotonin(5-HT2) receptor induced homologous and heterologous desensitization. Brain Res. 1993;631:349–351
  208. Fux M, Levine J, Aviv A, Belmaker RH. Inositol Treatment of Obsessive-compulsive Disorder. Am J Psychiatry. 1996;153:1219–1221
  209. Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH. Inositol treatment in psychiatry. [Review]. Psychopharmacol Bull. 1995;31:167–175
  210. Mahfouz NM, Smith TL, Kummerow FA. Changes of linoleic acid metabolism and cellular phospholipid fatty acid composition in LLC-PK cells cultured at low magnesium concentrations. Biochim Biophys Acta. 1989;1006:70–74
  211. Horrobin D F. Loss of delta-6-desaturase activity as a key factor in aging. Medical Hypotheses. 1981;7:1211–1220
  212. Stevens LJ, Zentall SS, Deck JL. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761–768
  213. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega3 polyunsaturated fatty acids in serum phospholiids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85:275–291
  214. Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY. Lowered omega3 polyunsaturated fatty acids in serum phospholiids and cholesteryl esters of depressed patients. Psychiatry Res. 1999;85:275–291
  215. Horrocks , L A, Yeo YK. Health Benefits of Docosahexaenoic Acid (DHA). Pharmacol Res. 1999;40:211–225
  216. Chalon S, Delion-Vancassel S, Belzung C. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr. 1998;128:2512–2519
  217. Boyle FG, Yuhas RJ, Lien EL. Red blood cell and tissue phospholipid fatty acid profiles of weanling rats fed infant formula fat blends containing soy and/or corn oil. Ann Nutr Metab. 1996;40:234–242
  218. Burtis CA, Ashwood ER. Tietz Textbook of Clinical Chemistry. Philadelphia: W. B. Saunders Company; 1994; p. 1953–1954
  219. Durlach J, Bac P, Durlach V, Bara M, Guiet-Bara A. Neurotic, neuromuscular and autonomic nervous form of magnesium imbalance. Magnes Res. 1997;10:169–195

PII: S0306-9877(01)91447-1

doi: 10.1054/mehy.2001.1447

Medical Hypotheses
Volume 58, Issue 1 , Pages 47-60 , January 2002

Article Tools